Allakos Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-08-28: Study NCT06577116; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2023-08-28: Study NCT06072157; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2022-10-26: Study NCT05528861; Company role Lead sponsor; Phase Phase 2; Status Terminated.
- 2022-06-27: Study NCT05155085; Company role Lead sponsor; Phase Phase 2; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-08-28 | NCT06577116 Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001 | Lead sponsor | Phase 1 | Completed | Chronic Spontaneous Urticaria | 29 | 2025-05-21 |
| 2023-08-28 | NCT06072157 Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria | Lead sponsor | Phase 1 | Completed | Healthy Participants; Chronic Spontaneous Urticaria | 136 | 2025-05-12 |
| 2022-10-26 | NCT05528861 A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria | Lead sponsor | Phase 2 | Terminated Results posted | Chronic Spontaneous Urticaria | 127 | 2024-04-18 |
| 2022-06-27 | NCT05155085 A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis | Lead sponsor | Phase 2 | Terminated Results posted | Atopic Dermatitis | 131 | 2024-04-17 |
| 2021-12 | NCT05152563 A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis | Lead sponsor | Phase 3 | Withdrawn | Eosinophilic Gastritis; Eosinophilic Duodenitis | 0 | 2022-01-20 |
| 2021-05-20 | NCT04856891 A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis | Lead sponsor | Phase 3 | Completed Results posted | Eosinophilic Duodenitis; Eosinophilic Gastroenteritis | 94 | 2023-01-09 |
| 2020-12-03 | NCT04620811 An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) | Lead sponsor | Phase 3 | Completed Results posted | Eosinophilic Gastritis; Eosinophilic Duodenitis | 159 | 2023-07-07 |
| 2020-07-06 | NCT04322708 A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis | Lead sponsor | Phase 2, Phase 3 | Completed Results posted | Eosinophilic Esophagitis | 277 | 2022-01-18 |
| 2020-06-18 | NCT04322604 A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) | Lead sponsor | Phase 3 | Completed Results posted | Eosinophilic Gastritis; Eosinophilic Duodenitis | 181 | 2022-01-12 |
| 2020-03-23 | NCT04324268 A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers | Lead sponsor | Phase 1 | Completed | Study Conducted in Healthy Volunteers | 66 | 2021-02-10 |
| 2018-11-14 | NCT03664960 An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis | Lead sponsor | Phase 2 | Completed Results posted | Eosinophilic Gastritis; Eosinophilic Gastroenteritis; Eosinophilic Duodenitis | 58 | 2021-11-02 |
| 2018-07-18 | NCT03496571 A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis | Lead sponsor | Phase 2 | Completed Results posted | Eosinophilic Gastritis; Eosinophilic Gastroenteritis | 65 | 2019-06-24 |
| 2018-02-26 | NCT03379311 A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis | Lead sponsor | Phase 1 | Completed | Atopic Keratoconjunctivitis; Vernal Keratoconjunctivitis; Perennial Allergic Conjunctivitis | 30 | 2019-08-08 |
| 2018-01-23 | NCT03436797 A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria | Lead sponsor | Phase 2 | Completed Results posted | Chronic Urticaria | 47 | 2020-04-06 |
| 2016-08 | NCT02859701 Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants | Lead sponsor | Phase 1 | Completed | Healthy | 51 | 2017-05-17 |
| 2016-06 | NCT02808793 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 | Lead sponsor | Phase 1 | Completed | Indolent Systemic Mastocytosis | 25 | 2018-12 |
| 2016-04 | NCT02734849 Study to Evaluate Multiple Doses in Patients With Nasal Polyposis | Lead sponsor | Phase 2 | Completed Results posted | Nasal Polyposis | 40 | 2018-01 |
| 2015-09 | NCT02563938 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 | Lead sponsor | Phase 1 | Completed | Atopy | 34 | 2016-03 |